 Connection
Ashley Frazer-Abel to Complement System Proteins
This is a "connection" page, showing publications Ashley Frazer-Abel has written about Complement System Proteins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.927 |
|
|
|
-
Proh?szka Z, Frazer-Abel A. Complement multiplex testing: Concept, promises and pitfalls. Mol Immunol. 2021 12; 140:120-126.
Score: 0.607
-
Frazer-Abel A, Kirschfink M, Proh?szka Z. Expanding Horizons in Complement Analysis and Quality Control. Front Immunol. 2021; 12:697313.
Score: 0.598
-
Willrich MAV, Braun KMP, Moyer AM, Jeffrey DH, Frazer-Abel A. Complement testing in the clinical laboratory. Crit Rev Clin Lab Sci. 2021 11; 58(7):447-478.
Score: 0.588
-
Frazer-Abel A. The effect on the immunology laboratory of the expansion in complement therapeutics. J Immunol Methods. 2018 10; 461:30-36.
Score: 0.486
-
Proh?szka Z, Kirschfink M, Frazer-Abel A. Complement analysis in the era of targeted therapeutics. Mol Immunol. 2018 10; 102:84-88.
Score: 0.481
-
Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Adv Clin Chem. 2016; 77:1-75.
Score: 0.420
-
Mandava N, Tirado-Gonzalez V, Geiger MD, Patnaik JL, Frazer-Abel A, Lynch AM, Mandava N, Palestine AG, Holers VM, Wagner BD, Sanchez-Santos I, Meizner D, Quiroz-Mercado H, Smith JM. Complement Activation in the Vitreous of Patients With Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2020 09 01; 61(11):39.
Score: 0.140
-
Brodszki N, Frazer-Abel A, Grumach AS, Kirschfink M, Litzman J, Perez E, Sepp?nen MRJ, Sullivan KE, Jolles S. European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management. J Clin Immunol. 2020 05; 40(4):576-591.
Score: 0.135
-
Chisholm CF, Behnke W, Pokhilchuk Y, Frazer-Abel AA, Randolph TW. Subvisible Particles in IVIg Formulations Activate Complement in Human Serum. J Pharm Sci. 2020 01; 109(1):558-565.
Score: 0.132
-
Bemis EA, Norris JM, Seifert J, Frazer-Abel A, Okamoto Y, Feser ML, Demoruelle MK, Deane KD, Banda NK, Holers VM. Complement and its environmental determinants in the progression of human rheumatoid arthritis. Mol Immunol. 2019 08; 112:256-265.
Score: 0.129
-
Proh?szka Z, Nilsson B, Frazer-Abel A, Kirschfink M. Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology. 2016 11; 221(11):1247-58.
Score: 0.105
-
Smith JM, Mandava N, Tirado-Gonzalez V, Garcia-Santisteban R, Geiger MD, Patnaik JL, Frazer-Abel A, Lynch AM, Mandava N, Holers VM, Wagner BD, Sanchez-Santos I, Meizner D, Quiroz-Mercado H, Palestine AG. Correlation of Complement Activation in Aqueous and Vitreous in Patients With Proliferative Diabetic Retinopathy. Transl Vis Sci Technol. 2022 04 01; 11(4):13.
Score: 0.039
-
Bomback AS, Appel GB, Gipson DS, Hladunewich MA, Lafayette R, Nester CM, Parikh SV, Smith RJH, Trachtman H, Heeger PS, Ram S, Rovin BH, Ali S, Arceneaux N, Ashoor I, Bailey-Wickins L, Barratt J, Beck L, Cattran DC, Cravedi P, Erkan E, Fervenza F, Frazer-Abel AA, Fremeaux-Bacchi V, Fuller L, Gbadegesin R, Hogan JJ, Kiryluk K, le Quintrec-Donnette M, Licht C, Mahan JD, Pickering MC, Quigg R, Rheault M, Ronco P, Sarwal MM, Sethna C, Spino C, Stegall M, Vivarelli M, Feldman DL, Thurman JM. Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2022 04; 79(4):570-581.
Score: 0.038
-
Thurman JM, Frazer-Abel A, Holers VM. The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis Rheumatol. 2017 11; 69(11):2102-2113.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|